PD-L1 (programmed death-ligand 1, B7-H1, CD274), the ligand for PD-1 inhibitory receptor, is expressed on various tumors, and its expression is correlated with a poor prognosis in melanoma. Anti-PD-L1 mAbs have been developed along with anti-CTLA-4 and anti-PD-1 antibodies for immune checkpoint inhibitor (ICI) therapy, and anti-PD-1 mAbs are now used as first line treatment in melanoma. However, many patients do not respond to ICI therapies, and therefore new treatment alternatives should be developed. Because of its expression on the tumor cells and on immunosuppressive cells within the tumor microenvironment, PD-L1 represents an interesting target for targeted alpha-particle therapy (TAT). We developed a TAT approach in a human melanoma xenograft model that stably expresses PD-L1 using a 213Bi-anti-human-PD-L1 mAb. Unlike treatment with unlabeled anti-human-PD-L1 mAb, TAT targeting PD-L1 significantly delayed melanoma tumor growth and improved animal survival. A slight decrease in platelets was observed, but no toxicity on red blood cells, bone marrow, liver or kidney was induced. Anti-tumor efficacy was associated with specific tumor targeting since no therapeutic effect was observed in animals bearing PD-L1 negative melanoma tumors. This study demonstrates that anti-PD-L1 antibodies may be used efficiently for TAT treatment in melanoma.

CAPITAO Marisa;  PERRIN Justine;  SIMON Sylvain;  GOUARD S.;  CHOUIN N;  BRUCHERTSEIFER Frank;  MORGENSTERN Alfred;  RBAH-VIDAL Latifa;  CHEREL M.;  SCOTET Emmanuel;  LABARRIERE N;  GUILLOUX Yannick;  GASCHET J; 

2021-07-15

MDPI

JRC124843

2072-6694 (online),   

https://publications.jrc.ec.europa.eu/repository/handle/JRC124843,   

10.3390/cancers13061256 (online),